LOGIN  |  REGISTER
Amneal Pharmaceuticals
C4 Therapeutics

Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

May 21, 2025 | Last Trade: US$11.25 0.06 0.54

VAUGHAN, Ontario / May 21, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the “Annual Meeting”) held on May 21, 2025. Detailed results of the vote follow:

Name

 

For

 

Against

 

Broker Non-Votes

Nathalie Bernier

 

337,617,248

 

1,924,336

 

8,383,437

Gary Hu

 

337,591,706

 

1,949,878

 

8,383,437

Brett Icahn

 

337,474,287

 

2,067,297

 

8,383,437

Sarah B. Kavanagh

 

337,602,211

 

1,939,373

 

8,383,437

Karen L. Ling

 

337,526,114

 

2,015,470

 

8,383,437

John A. Paulson

 

337,650,735

 

1,890,849

 

8,383,437

Russel C. Robertson

 

337,600,880

 

1,940,704

 

8,383,437

Thomas W. Ross, Sr.

 

337,583,018

 

1,958,566

 

8,383,437

Brenton L. Saunders

 

337,592,062

 

1,949,522

 

8,383,437

Andrew C. von Eschenbach, M.D.

 

337,607,276

 

1,934,308

 

8,383,437

Shareholders also approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers, appointment of PricewaterhouseCoopers LLP to serve as auditor until the close of the Company's 2026 Annual Meeting of Shareholders, and authorization for the board of directors to fix the auditor’s remuneration.

The final vote tabulation on all matters voted on at the Annual Meeting will be filed with the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR+ profile and on the Company’s website at www.bausch.com.

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

Recursion

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page